Phaseline

Targets › PTPRZ1

PTPRZ1 (Receptor-type tyrosine-protein phosphatase zeta): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Protein tyrosine phosphatase that negatively regulates oligodendrocyte precursor proliferation in the embryonic spinal cord. Required for normal differentiation of the precursor cells into mature, fully myelinating oligodendrocytes. (UniProt, P23471)

Open in Phaseline: the race on PTPRZ1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Assistance Publique - Hôpitaux de ParisCancer vaccine against TERT and PTPRZ1
Cancer vaccine targeting glioma-associated antigens (TERT and PTPRZ1)
TERT, PTPRZ1Phase 1Newly Diagnosed GlioblastomaMar 2028

Conditions

Newly Diagnosed Glioblastoma (1)

Modalities

protein or peptide (1)

Companies

Assistance Publique - Hôpitaux de Paris (1)

Related targets

TERT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.